Compare PROF & NHS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PROF | NHS |
|---|---|---|
| Founded | N/A | 2003 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 248.8M | 251.6M |
| IPO Year | 2017 | N/A |
| Metric | PROF | NHS |
|---|---|---|
| Price | $5.68 | $5.66 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $12.00 | N/A |
| AVG Volume (30 Days) | 120.7K | ★ 144.1K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 13.44% |
| EPS Growth | ★ 25.89 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $16,098,000.00 | N/A |
| Revenue This Year | $92.40 | N/A |
| Revenue Next Year | $64.10 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 50.73 | N/A |
| 52 Week Low | $3.92 | $5.85 |
| 52 Week High | $8.95 | $7.75 |
| Indicator | PROF | NHS |
|---|---|---|
| Relative Strength Index (RSI) | 27.52 | 22.82 |
| Support Level | $4.97 | N/A |
| Resistance Level | $6.06 | $6.12 |
| Average True Range (ATR) | 0.35 | 0.05 |
| MACD | -0.10 | -0.01 |
| Stochastic Oscillator | 16.23 | 15.38 |
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.
Neuberger Berman High Yield Strategies Fund Inc is a diversified, closed-end management investment company. The company invests in high yield debt securities market. The Fund uses leverage to pursue its investment objective. The Fund may invest in a variety of direct debt instruments, including bank loans, notes and other interests in amounts owed to financial institutions by borrowers, such as companies and governments. Corporate loans in which the Fund may invest will consist of direct obligations of borrowers. The Fund may invest in corporate loans at origination as a co-lender or may acquire loans in the secondary market by purchasing participations in, assignments of or novations of corporate loans.